Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More
Xconomy
OCTOBER 7, 2016
military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy.
Let's personalize your content